Vistagen announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market indicating that Vistagen has regained full compliance with the minimum $1.00 bid price per share or greater requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Vistagen is now in full compliance with all applicable Nasdaq listing requirements, and Nasdaq considers the matter closed.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VTGN:
- Vistagen: Data from PH-10 study allows Phase 2B development for MDD treatment
- Vistagen: EPO issues intention to grant patent for PH80 nasal spray for migraine
Questions or Comments about the article? Write to editor@tipranks.com